Trial Profile
A single ascending dose trial of PRT 062607 in volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Aug 2016
Price :
$35
*
At a glance
- Drugs PRT 062607 (Primary)
- Indications Cancer; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Portola Pharmaceuticals
- 13 Jul 2016 Results published in the Journal of Clinical Pharmacology
- 25 Mar 2010 New trial record